- Home
- REFI vs XOMA Comparison
REFI vs XOMA Comparison
Compare REFI & XOMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REFI
- XOMA
- Stock Information
- Founded
- REFI 2021
- XOMA 1981
- Country
- REFI United States
- XOMA United States
- Employees
- REFI N/A
- XOMA N/A
- Industry
- REFI Real Estate Investment Trusts
- XOMA Biotechnology: Pharmaceutical Preparations
- Sector
- REFI Real Estate
- XOMA Health Care
- Exchange
- REFI Nasdaq
- XOMA Nasdaq
- Market Cap
- REFI 304.4M
- XOMA 330.2M
- IPO Year
- REFI 2021
- XOMA N/A
- Fundamental
- Price
- REFI $14.25
- XOMA $26.96
- Analyst Decision
- REFI Strong Buy
- XOMA Strong Buy
- Analyst Count
- REFI 3
- XOMA 2
- Target Price
- REFI $20.00
- XOMA $69.50
- AVG Volume (30 Days)
- REFI 105.4K
- XOMA 78.7K
- Earning Date
- REFI 08-06-2025
- XOMA 08-12-2025
- Dividend Yield
- REFI 13.19%
- XOMA N/A
- EPS Growth
- REFI N/A
- XOMA N/A
- EPS
- REFI 1.88
- XOMA N/A
- Revenue
- REFI $56,790,054.00
- XOMA $42,909,000.00
- Revenue This Year
- REFI $15.53
- XOMA $70.91
- Revenue Next Year
- REFI $6.70
- XOMA $14.00
- P/E Ratio
- REFI $7.58
- XOMA N/A
- Revenue Growth
- REFI 4.68
- XOMA 638.41
- 52 Week Low
- REFI $12.76
- XOMA $18.35
- 52 Week High
- REFI $16.47
- XOMA $35.00
- Technical
- Relative Strength Index (RSI)
- REFI 48.62
- XOMA 56.91
- Support Level
- REFI $13.85
- XOMA $24.87
- Resistance Level
- REFI $14.59
- XOMA $28.09
- Average True Range (ATR)
- REFI 0.29
- XOMA 1.32
- MACD
- REFI 0.01
- XOMA 0.07
- Stochastic Oscillator
- REFI 51.76
- XOMA 70.40
About REFI Chicago Atlantic Real Estate Finance Inc.
Chicago Atlantic Real Estate Finance Inc is engaged in a commercial real estate finance company. Its primary investment objective is to provide attractive risk-adjusted returns for stockholders over time, through consistent current income dividends and other distributions and secondarily through capital appreciation.
About XOMA XOMA Corporation
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes. Geographically, the company operates in Switzerland, United States, Asia Pacific, Europe and Others.